Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis

医学 任天堂 吡非尼酮 特发性肺纤维化 内科学 危险系数 队列 置信区间 队列研究 倾向得分匹配 肺
作者
Timothy Dempsey,Lindsey R. Sangaralingham,Xiaoxi Yao,Darshak Sanghavi,Nilay D. Shah,Andrew H. Limper
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:200 (2): 168-174 被引量:119
标识
DOI:10.1164/rccm.201902-0456oc
摘要

Rationale: Since their approval, there has been no real-world or randomized trial evidence evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically important outcomes such as mortality and hospitalizations.Objectives: To evaluate the clinical effectiveness of the antifibrotic medications pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis.Methods: Using a large U.S. insurance database, we identified 8,098 patients with idiopathic pulmonary fibrosis between October 1, 2014 and March 1, 2018. A one-to-one propensity score–matched cohort was created to compare patients treated with antifibrotic medications (n = 1,255) with those not on treatment (n = 1,255). The primary outcome was all-cause mortality. The secondary outcome was acute hospitalizations. Subgroup analyses were performed to evaluate mortality differences by drug.Measurements and Main Results: The use of antifibrotic medications was associated with a decreased risk of all-cause mortality (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.62–0.98; P value = 0.034). However, this association was present only through the first 2 years of treatment. There was also a decrease in acute hospitalizations in the treated cohort (HR, 0.70; 95% CI, 0.61–0.80; P value <0.001). There was no significant difference in all-cause mortality between patients receiving pirfenidone and those on nintedanib (HR, 1.14; 95% CI, 0.79–1.65; P = 0.471).Conclusions: Among patients with idiopathic pulmonary fibrosis, antifibrotic agents may be associated with a lower risk of all-cause mortality and hospitalization compared with no treatment. Future research should test the hypothesis that these treatments reduce early, but not long-term, mortality as demonstrated in our study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
热心市民小红花的应助被yyj采纳,获得10
刚刚
秋冥发布了新的文献求助10
刚刚
星辰大海的应助被熊已无心采纳,获得10
1秒前
锦鲤旺旺发布了新的文献求助10
1秒前
Du发布了新的文献求助10
1秒前
思源的应助被Ffan采纳,获得10
1秒前
1秒前
才思敏捷的橙子完成签到,获得积分10
2秒前
ddddd发布了新的文献求助10
2秒前
脑洞疼的应助被aran采纳,获得10
2秒前
李JJ完成签到,获得积分10
3秒前
承久完成签到,获得积分10
3秒前
任性背包完成签到,获得积分10
3秒前
4秒前
孙文远留下了新的社区评论
4秒前
4秒前
CHEN发布了新的文献求助10
5秒前
null的应助被fortuna采纳,获得10
5秒前
dd完成签到,获得积分10
5秒前
瓦学弟的妈妈完成签到,获得积分10
5秒前
didida发布了新的文献求助30
6秒前
6秒前
科研通AI6.2的应助被SHY采纳,获得10
6秒前
yly发布了新的文献求助10
6秒前
陈醉发布了新的文献求助10
6秒前
7秒前
7秒前
8秒前
微弱de胖头完成签到,获得积分20
8秒前
lcyswlk完成签到,获得积分10
8秒前
脑洞疼的应助被ddddd采纳,获得10
9秒前
柚子糖完成签到,获得积分10
9秒前
9秒前
开朗的从灵完成签到,获得积分10
9秒前
qingsan发布了新的文献求助10
10秒前
10秒前
hhh关闭了hhh的文献求助
10秒前
默默发布了新的文献求助10
10秒前
小饼干发布了新的文献求助10
10秒前
今后的应助被yly采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161554
求助须知:如何正确求助?哪些是违规求助? 9556174
关于积分的说明 21732775
捐赠科研通 7751537
什么是DOI,文献DOI怎么找? 3427556
关于科研通互助平台的介绍 2552588
邀请新用户注册赠送积分活动 2472023